Psychiatry and Clinical Neurosciences
April 18, 2023
Lucy Chester, Lucia Valmaggia, Matthew J. Kempton et al.
Evidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However, there have been limited prospective studies and the direction of this association remains controversial. The primary aim of the present study was to examine the association between cannabis use and the incidence of psychotic disorders in people at clinical high risk of...
Schizophrenia Research: Cognition
December 11, 2018
Luccas Coutinho, Hianna Honorato, Cinthia Hiroko Higuchi et al.
8 citations
INTRODUCTION: Cannabis use increases the risk of developing psychosis, and subjects with psychosis are more likely to use cannabis. However, studies on the influence of cannabis on psychotic dimensions, response to treatment, and functional outcomes showed conflicting results. Such heterogeneity may be due the inclusion of patients who were already under treatment, and lack of specificity in...
Schizophrenia Bulletin
April 1, 2018
Luccas Coutinho, Cinthia H Higuchi, Daniel A. Cavalcante et al.
Abstract Background Psychotic disorders induced by cannabis may present distinct symptomatic profile, course and underlying biology. Most studies on symptomatic effects of cannabis exposure are limited by examining patients after antipsychotic treatment. We investigated if antipsychotic naive FEP patients that reported cannabis use present higher symptom’s severity and if affects deferentially...
December 1, 2017
Tatiana M N Rezende, J. P. Maia-De-Oliveira, Ludmyla Kandratavicius et al.
Background: Recent evidence has shown improvements in schizophrenia symptoms after the infusion of sodium nitroprusside (SNP), a nitric oxide (NO) donor. In the rat model of schizophrenia using ketamine injection, pretreatment with SNP seems to prevent behavioral changes associated with positive symptoms for up to one week. Objective: We investigated whether SNP would have preventative effects...
The British Journal of Psychiatry
May 31, 2011
Maria Alice Fontes, Karen I Bolla, Paulo Jannuzzi Cunha et al.
300 citations
BACKGROUND: Many studies have suggested that adolescence is a period of particular vulnerability to neurocognitive effects associated with substance misuse. However, few large studies have measured differences in cognitive performance between chronic cannabis users who started in early adolescence (before age 15) with those who started later. AIMS: To examine the executive functioning of...
Brazilian Journal of Psychiatry
March 1, 2008
Priscila Previato Almeida, Maria Alice Fontes Pinto Novaes, Rodrigo A. Bressan et al.
24 citations
OBJECTIVE: Cannabis is the most used illicit drug worldwide, however only a few studies have examined cognitive deficits related to its use. Clinical manifestations associated with those deficits include a motivational syndrome, impairment in cognitive flexibility, inattention, deficits in abstract reasoning and concept formation, aspects intimately related to the executive functions, which...